On Oct. 5, 2025, Eli Lilly ill invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, as it seeks to tap into skilled workforce to bolster its global manufacturing expansion. The collaborations aim to increase the availability of Lilly’s key drugs, including those for obesity, diabetes, Alzheimer’s, cancer and autoimmune conditions, the company said.

The company, which launched its blockbuster weight-loss drug Mounjaro in India this year, currently does not operate its own manufacturing facility in the country, which hosts several firms that develop and manufacture complex drugs, vials, injectables for larger pharmaceuticals on a contract basis.

Separately, Lilly is setting up a manufacturing and quality facility in the southern Indian city of Hyderabad to expand its presence beyond the city’s global capability center. The new hub will oversee the firm’s contract manufacturing network across India and provide technical capabilities.